WASHINGTON Die amerikanische Arzneimittelzulassungsbehörde FDA bestätigt zwei weitere PML-Erkrankungen in Europa und den USA. … weiter »
WASHINGTON Die amerikanische Arzneimittelzulassungsbehörde FDA bestätigt zwei weitere PML-Erkrankungen in Europa und den USA. … weiter »
I am sorry I do not speak German but I get the gist of your work. I hope you do not have a problem with my writing in English.
First, I would like to thank you and congratulate you on your work which provides scarce information on Tysabri and PML during the last 1,5 month (and even before).
Secondly, I would like to ask whether you have further information for current or former Tysabri users. I ask because after 18 months of treatment that stopped lesion activity in my brain, 2 months ago I decided to quit Tysabri because my spinal MRI shows a lot of MS damage and at the functional level I have not witnessed any stability and declined very much since starting Tysabri. Furthermore, your data shows that 4 out of 13 persons were diagnosed with PML between 12 and 17 months of treatment. Although I quit this medication I still am concerned that I might be at risk. Do you have any information of rebound effect or PML emergence after quitting?
Thank you for your attention,
Best regards.
Huri
Hi Huri,
thanx for your nice Fedback. Try this for further infos about rebound effcts: Immunologic and clinical status 14 months after cessation of natalizumab therapy [PMID: 18987352]
Best regards
Alex